MRNA is trading 5.1% up today at $48.06 as the biotech sector bounces back amid easing interest rate jitters and renewed dip-buying interest.
- The stock is recovering from recent weakness linked to surging Treasury yields, which had previously pressured growth and biotech valuations broadly.
- Today’s price action appears to be driven by macro and sector-wide sentiment rather than any new company-specific fundamental developments.